CJC-1295 Research Peptide of US Peptides Increasingly Used in HGH Studies
CJC-1295 (http://www.uspeptides.com) research peptide, a long acting growth hormone releasing factor (GHRH) of US Peptides is being increasingly used in clinical trails and research studies.
Clearwater, FL - CJC-1295 (http://www.uspeptides.com) research peptide is a long acting growth hormone release factor (GHRH) peptide that US Peptides LLC, reports is being increasingly used around the world in research studies and clinical trials.
Peptides are chains of amino acid residues with remarkable biological functions, ranging from hormonal regulation to antibiotic activities.
The U.S. Clinical Trials website reports 21 trials currently in one of several stages of development using growth hormone releasing factor (CJC-1295). Subjects of the studies including research for anti-aging, obesity, mastocytosis, congestive heart failure, sleep disorders, HIV, lung cancer, Type 1 Diabetes and more. Not only are a myriad of studies being conducted for the many facets of anti-aging and adult health issues, there are studies underway for childhood illnesses as well.
More expansively put, peptide research includes synthesis of biologically important targets, isolation and characterization of new products, and structure-activity relationship studies. And while the lay person may not understand what CJC-1295, IGF-LR3 or even a peptide is, they will most certainly appreciate the benefits of successful research.
"As the boomer population ages, demand for research and clinical trails seems to have mushroomed and we are experiencing the rapid growth of this industry with a large portion of the studies being conducted with CJC-1295," says Don Pierce, Founder of US Peptides LLC.
CJC-1295 is provided by US Peptides, LLC (http://www.uspeptides.com) founded in 2010 to work with researchers doing studies and clinical trials with peptides. In addition to CJC-1295 research peptide, US Peptides also provides researchers with other much in demand peptides including GHRP, Melanotan, Semorelin, IGF-LR3, Growth Factor, GHRP 2, Hexarelin, MGF, MGF Ipamorelin, Mechano Growth Factor, and IGF. Disclaimer: All products listed and provided through USPeptides.com are intended for research purposes only. We do not promote the personal use of these products. Products provided by USPeptides.com are not intended for use in food products or as any type of drug. Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition and are for research purposes only.
Media Contact:
Jeannine Dowdell
727-461-9635
http://www.theonlineprplace.com
Press release courtesy of Online PR Media: http://bit.ly/i3DRvt
Clearwater, FL - CJC-1295 (http://www.uspeptides.com) research peptide is a long acting growth hormone release factor (GHRH) peptide that US Peptides LLC, reports is being increasingly used around the world in research studies and clinical trials.
Peptides are chains of amino acid residues with remarkable biological functions, ranging from hormonal regulation to antibiotic activities.
The U.S. Clinical Trials website reports 21 trials currently in one of several stages of development using growth hormone releasing factor (CJC-1295). Subjects of the studies including research for anti-aging, obesity, mastocytosis, congestive heart failure, sleep disorders, HIV, lung cancer, Type 1 Diabetes and more. Not only are a myriad of studies being conducted for the many facets of anti-aging and adult health issues, there are studies underway for childhood illnesses as well.
More expansively put, peptide research includes synthesis of biologically important targets, isolation and characterization of new products, and structure-activity relationship studies. And while the lay person may not understand what CJC-1295, IGF-LR3 or even a peptide is, they will most certainly appreciate the benefits of successful research.
"As the boomer population ages, demand for research and clinical trails seems to have mushroomed and we are experiencing the rapid growth of this industry with a large portion of the studies being conducted with CJC-1295," says Don Pierce, Founder of US Peptides LLC.
CJC-1295 is provided by US Peptides, LLC (http://www.uspeptides.com) founded in 2010 to work with researchers doing studies and clinical trials with peptides. In addition to CJC-1295 research peptide, US Peptides also provides researchers with other much in demand peptides including GHRP, Melanotan, Semorelin, IGF-LR3, Growth Factor, GHRP 2, Hexarelin, MGF, MGF Ipamorelin, Mechano Growth Factor, and IGF. Disclaimer: All products listed and provided through USPeptides.com are intended for research purposes only. We do not promote the personal use of these products. Products provided by USPeptides.com are not intended for use in food products or as any type of drug. Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition and are for research purposes only.
Media Contact:
Jeannine Dowdell
727-461-9635
http://www.theonlineprplace.com
Press release courtesy of Online PR Media: http://bit.ly/i3DRvt
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- Musical Artist Miss Kristin Invites Robert Berry To Production On Wayward Son [22 May 2012] Wired PR News
- Magid Glove & Safety Launches New CutMaster(R) Aramax(TM) and Aramax(TM) XT Gloves and Sleeves [22 May 2012] 24-7 pressrelease
- Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock [22 May 2012] PR Newswire
- STAG Industrial, Inc. Announces Pricing Of Public Offering Of Common Stock [22 May 2012] PR Newswire





